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INTRODUCTION
Apixaban (BMS-562247, Figure 1 ) is an oral anticoagulant in late-stage clinical development for the prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation and secondary prevention in acute coronary syndrome. It is a potent, oral, reversible, selective and direct factor Xa (FXa) inhibitor, which inhibits both free and prothrombinase-bound FXa activity, and shows considerable efficacy in the prevention of arterial and venous thrombosis at doses that preserved hemostasis in rabbits (Pinto et al., 2007; Wong et al., 2008) . It is also effective and safe for the prevention and treatment of venous thrombosis in man (Lassen et al., 2007; Büller et al., 2008) . After oral administration of apixaban to human subjects, the parent compound was the major circulating component and O-demethyl apixaban sulfate ( Figure 1 ) was a significant metabolite in human plasma; however, it was not as abundant relative to parent in plasma samples of mice, rats, female rabbits, and dogs ). Apixaban probably underwent O-demethylation catalyzed by P450 enzymes to O-demethylated apixaban that was then conjugated by sulfotransferases to form a sulfate metabolite.
Sulfation is a major conjugation reaction of drug metabolism, and the sulfotransferases (SULTs) are responsible for sulfation biotransformation of many xenobiotics and endogenous substrates such as steroids and neurotransmitters in humans (Blanchard et al., 2004; Nagata and Yamazoe, 2000; Rikke and Roy, 1996) . The process of sulfation involves the transfer of a sulfonyl group of PAPS to a hydroxyl or amino group of a molecule. This reaction generally results in a decrease in biological activity and an increase in hydrophilicity of xenobiotics (drugs) or endogenous compounds, so as to facilitate their excretion. SULTs play an important role in normal human homeostasis and DMD 025593 5 drug metabolism (Gamage et al., 2006; Glatt et al., 2000) . For example, SULT1E1 is responsible for the high affinity sulfation of β -estradiol (E2), estrone, and 17α-ethinylestradiol (Adjei et al., 2003; Falany et al., 1995; Schrag et al., 2004) . SULT1A1
catalyzes the sulfation of many xenobiotics and is expressed in many tissues including liver and small intestine (Chen et al., 2002; LeWitt, 2004) .
Sulfotransferases are a superfamily of enzymes that catalyze the sulfate conjugation of various antibiotics and xenobiotics. Five gene families of SULTs, including SULT1, SULT2, SULT3, SULT4, and SULT5, have been identified in mammals. There is less than 45% amino acid sequence identity between families (Blanchard et al., 2004) . In humans, thirteen SULTs have been identified, all belonging to the SULT1, SULT2, or SULT4 families (Gamage et al., 2006; Glatt et al., 2000; Glatt et al., 2001 ). Human SULT1A1 shows high homology with SULT1A2 (96%). Expression of SULT1A1, 1A3, 1B1, 1B2, 1E1, 1E4, 2A1, and 2A3 in adult human livers was documented and characterized (Honma et al., 2002; Richard et al., 2001; Tabrett et al., 2003) . SULT1A1 is the dominant SULT1A protein expressed in human liver (Gamage et al., 2006) , and there are three important allelic variants, SULT1A1*1 (wild type), SULT1A1*2 and SULT1A1*3. SULT1A1*2 is defined by an Arg213His amino acid change (G to A change at nucleotide 638), and SULT1A1*3 variant is defined by a Met223Val amino acid change (A to G change at nucleotide 667) (Carlini et al., 2001) . SULT1A1 allele frequencies have been reported in different populations (Carlini et al., 2001) : 65.6%
(white), 47.7% (African American), and 91.4% (Chinese) for SULT1A1*1; 33.2%
(white), 29.4% (African American), and 8.0% (Chinese) for SULT1A1*2; 1.2% (white), 22.9% (African American), and 0.6% (Chinese) for SULT1A1*3. These alloenzymes are DMD 025593 6 associated with altered enzymatic activities (Nagar et al., 2006; Raftogianis et al., 1997) .
The general trend of V max values estimated in previous study was *1>*3>*2, with trend of V max /K m values varied with substrates (Raftogianis et al., 1997) . A total of 6 alloenzymes of SULT1A2 have been reported (Raftogianis et al., 1999) . Human SULT1A3 showed 93% similarity to SULT1A1 (Blanchard et al., 2004; Gamage et al., 2006) . No genetic polymorphisms have been reported for SULT1A3 and SULT1E1 at the DNA level.
SULT2A1 is also a major enzyme located in human liver and involved in drug metabolism (Meloche et al., 2002) .
In this study, the sulfation activities of human cDNA-expressed SULTs as well as liver S9 from mice, rats, rabbits, dogs, monkeys, and humans on O-demethyl apixaban were investigated to determine the principal SULT enzymes involved in this sulfation reaction and to compare enzyme activities between species.
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glycyl-L-arginine-para-nitroaniline hydrochloride and its glutamyl methyl ester (1:1 mixture)), which were purchased from DiaPharma Group, Inc (West Chester, OH). Raghavan et al., 2009) . Plasma samples were extracted in duplicate by addition of 4 mL of acetonitrile/methanol (1:1, v/v) to 1 mL of plasma while the sample was mixed on a vortex mixer. After centrifugation at 2000 x g for 1 h, each supernatant fraction was removed and saved. The precipitate was resuspended in 2 mL of acetonitrile and 1 mL of methanol. Following centrifugation of the mixture for 30 min at 2000 x g, the supernatant fraction was removed and combined with the first supernatant.
The precipitate was resuspended in 2 mL acetonitrile. Following centrifugation of the mixture at 2000 x g for 30 min, the supernatant fraction was removed and combined with the first and second supernatants. The combined supernatant fraction was evaporated to dryness under nitrogen and reconstituted in 0.15 mL of acetonitrile and 0.05 mL of methanol. Following centrifugation at 2000 x g for 5 min, a portion of 100 μL supernatant was injected into the HPLC for metabolite profiling and identification.
Assessment of pharmacological activities of O-demethyl apixaban and O-demethyl
apixaban sulfate. The enzyme activities of factor Xa, alpha-thrombin, and trypsin were determined as described previously (Pinto et. al, 2007; Wong et al., 2008 
Sulfation assays in liver S9 of different species. Sulfation activities of O-demethyl
apixaban were determined using liver S9 fractions from mice, rats, and rabbits, dogs, monkeys, or humans, and O-demethyl apixaban as substrate. Incubation mixtures (0.5 mL, in triplicate) contained 50 mM potassium phosphate buffer (pH 7.5), 5 mM MgCl 2 , liver S9 (100 μg protein), 30 μM O-demethyl apixaban, and 2.5 mM PAPS. Before addition of PAPS, the mixtures were pre-incubated at 37°C for 5 min. After 30 min incubation at 37°C with shaking (100 rpm), ice-cold acetonitrile (0.5 mL) was added to each incubation to stop the reaction and the internal standard (IS, apixaban) was added to each sample to a final concentration of 100 nM. After centrifugation at 2000 x g for 15 min, an aliquot of supernatant (10 or 20 μL) was used for LC/MS analysis.
Substrate concentration-dependent sulfate formation. For enzyme kinetic studies, the incubation mixtures (0.5 mL) contained 50 mM phosphate buffer (pH 7.5), 5 mM MgCl 2 , human liver S9 (150 μg protein) or expressed SULTs (20 pmole), O-demethyl apixaban, and 2.5 mM PAPS. The final concentration of acetonitrile in these incubation mixtures was 0.5% (v/v). Before PAPS addition, the mixtures were pre-incubated at 37°C for 5 min. After PAPS addition, the samples were then incubated at 37°C for 30 min with shaking (100 rpm), then ice-cold acetonitrile (0.5 mL) was added to each sample to stop reaction and the internal standard (IS, apixaban) was added to each sample to a final concentration of 100 nM. An aliquot of 20 μL of supernatant was used for LC/MS analysis. In order to determine linear conditions for protein concentration and incubation time, O-demethyl apixaban (10 μM) was incubated up to 50 min with 100, 200, 300, and 600 μg of human liver S9 protein/mL; O-demethyl apixaban (10 μM) was incubated up to 50 min with human cDNA-expressed SULTs at 8 to 20 μg protein/mL: 8.8 μg protein/mL This article has not been copyedited and formatted. The final version may differ from this version. μM were evaluated in triplicate for human liver S9.
Identification and quantification of sulfate metabolite. Metabolites in human plasma samples of rats and human were analyzes as described previously ).
Metabolites in samples of incubations were analyzed by LC/MS/MS method. For incubation samples, after termination of the incubation, an internal standard was added to the reaction mixture. LC/MS analysis was performed on a Finnigan LTQ mass spectrometer (ThermoFisher Scientific, San Jose, CA) with an ESI probe in a positive ion mode. The HPLC system was a HEWLETT ® PACKARD Agilent 1100 series system equipped with two pumps, an autoinjector, a UV detector, and an ACE ® 3 C18 column (4.6 mm x 150 mm). The mobile phase consisted of two solvents: A) 0.4% formic acid in water, pH 3.2, and B) 100% acetonitrile. The gradient employed was as follows: Solvent B started at 5%, then linearly increased to 20% at 5 min, to 30% at 50 min, to 35% at 55 min, to 90% at 65 min, held at 90% for 2 min, and then decreased to 5% at 69 min. The mobile phase flow rate was 0.7 mL/min. The HPLC effluent was directed to the mass spectrometer through a valve set to divert the flow to waste from 0 to 5 min. The capillary temperature used for analysis was set at 250 o C. The gas flow rate of nitrogen, spray current, and voltages were adjusted to give maximum sensitivity using apixaban as a standard. For metabolite quantification in incubation samples, the detection was This article has not been copyedited and formatted. The final version may differ from this version. 
Pharmacological activities of O-demethyl apixaban and O-demethyl apixaban sulfate.
The enzyme activities for factor Xa, thrombin, and trypsin were determined using paranitroaniline coupled peptides as substrates (S2765, S2366, and S2222). Under these conditions, K m values were 23.6, 220, and 31 μM for factor Xa, thrombin, and trypsin, respectively. The significant inhibition for factor Xa was observed only at high This article has not been copyedited and formatted. The final version may differ from this version. (Pinto et al., 2007) and a K i value of >15,000 nM for inhibition of trypsin.
Sulfation activity by various recombinant SULTs. Among five recombinant human
SULTs screened for the sulfation activity, all generated O-demethyl apixaban sulfate. In human cDNA-expressed SULTs, the sulfation activities followed a decreasing order of SULT1A1 > SULT1A2 >> SULT1E1 > SULT1A3 ≈ SULT2A1 (Table 1 and Figure 3 ).
Inhibition studies. The sulfation activity of O-demethyl apixaban was determined with human liver S9 in the presence of SULT inhibitors (Table 2 and Figure 4 ). Quercetin (1 μM) inhibited the formation of O-demethyl apixaban sulfate by 99%; DCNP (0.5 μM), a high selective inhibitor for SULT1A1 (IC 50 < 0.1 μM), also inhibited the formation of Odemethyl apixaban sulfate by >90%; estrone, which has a high selectivity for SULT1E1, showed no effect at 1 μM concentration on the formation of O-demethyl apixaban sulfate.
The inhibition results indicated that SULT1A1 is likely the major sulfotransferase catalyzing the sulfation of O-demethyl apixaban in humans.
Species comparison of O-demethyl apixaban sulfation. The formation of O-demethyl
apixaban sulfate was observed in all liver S9 incubations and the formation rates are shown in Table 3 and Figure 5 . Relatively low levels of sulfation activities (from ~1 to 11
DISCUSSION
The radioactivity profiles of plasma at 24 h post dose showed that both apixaban and Odemethyl apixaban sulfate were prominent circulation components in humans and while apixaban was dominant component in rats. O-Demethyl apixaban was a minor metabolite detected by LC/MS analysis only in plasma samples of early time points (6 h) ). In addition, O-Demethyl apixaban and O-demethyl apixaban sulfate did not significantly inhibit purified human factor Xa. The affinity constants (K i ) were 20 nM and 58 μM for O-demethyl apixaban and O-demethyl apixaban sulfate, respectively, over 250-fold less potent than apixaban (Pinto et al., 2007) . In contrast, the K i of apixaban for human factor Xa is 0.08 nM. Based on K i values and human plasma profiles (apixaban accounting for over 61% radioactivity), the μ M. The lack of affinity for factor Xa, thrombin, and trypsin suggest that O-demethyl apixaban sulfate is also unlikely to inhibit other serine proteases at low μM concentrations that achieved after administration of apixaban in humans ).
The identification of the SULTs involved in the sulfation of O-demethyl apixaban was carried out with initial screening of metabolic turnover by cDNA-expressed enzymes followed by evaluation of the effects of chemical inhibitors on sulfation reation in human liver S9. Upon initial screening with cDNA-expressed enzymes, multiple SULTs This article has not been copyedited and formatted. The final version may differ from this version. (Walle et al., 1995; Schrag et al., 2004) . In the present study, results showed that quercetin (1 μM) and DCNP (0.5 μM) selectively inhibited the formation of O-demethyl apixaban sulfate by >90% in human liver S9 incubations at 20
and 100 μM of O-demethyl apixaban (Figure 4 ). In contrast, estrone which is a high affinity inhibitor for SULT1E1 with a K m value of approximate 6 nM (Schrag et al., 2004) , had no significant effect on the formation of O-demethyl apixaban sulfate in human liver S9 incubations at 20 and 100 μM of O-demethyl apixaban (Figure 3 ). These data suggested that SULT1A1 plays an important role in the formation of O-demethyl apixaban sulfate. n = 6 for mouse, rat, dog, monkey, and human liver S9; CV (%) were from 44% to 118%; n = 3 for male and female rabbit liver S9; CV (%) were from 9.8% to 26%. 
